Two top pharmaceutical trade groups have asked a federal judge to block a controversial Nevada law that requires certain diabetes drugmakers to disclose information to the state about the costs of making and marketing the medications. In a lawsuit filed Sept. 1 in the federal district court in Las Vegas, the Pharmaceutical Research and Manufacturers of America (PhRMA), a nonprofit advocacy group representing the pharmaceutical industry, and Biotechnology Innovation Organization (BIO) argue that the state law is unconstitutional and violates federal patent and trade secret rights.
The law, signed by Nevada Gov. Brian Sandoval in June, is an attempt to curb soaring prescription drug prices or, at a minimum, provide consumers with information about why the costs are so high. It requires manufacturers who have raised diabetes drugs’ list prices by a certain amount to report that information along with the rebates they provided to the state Department of Health and Human Services.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
